Letters by company
Aroa Biosurgery Ltd
4 letters discussing ARX. Everything written about it on this site is on its ticker page.
- Forager Funds Management Monthly Report April 2026 Forager Australian Shares Fund deployed cash amid volatility, reducing its cash position as smaller industrials lagged while resources and technology rallied. Cuscal’s Paymark acquisition was viewed as a logical, accretive use of capital, while EML Payments cut expectations and Hipages and Aroa reported favourable operating updates. April 2026 CCL $669M
- Forager Funds Management Monthly Report | October 2025 Forager Australian Shares Fund sold Bravura Solutions after its outlook upgrade drove volatility, judging a material growth uplift necessary to support the valuation. It expects Caterpillar's acquisition of RPMGlobal to close in February and considers the bid fair, while Praemium and Aroa Biosurgery issued encouraging updates and OFX disappointed. October 2025 BVS $947M
- Forager Funds Management Monthly Report | November 2024 The Forager Australian Shares Fund cited Catapult’s accelerating recurring revenue, positive free cash flow and expanding margins as support for continued growth. EML Payments’ strategy update eased market concerns, while Praemium, Aroa Biosurgery and Tyro Payments supported the investment theses; Camplify reported weak trading across several markets. November 2024 CAT $561MEML $65M
- Forager Funds Management Monthly Report | October 2024 Forager Australian Shares Fund added meaningfully to Tyro Payments after proposed debit-card surcharge reforms prompted a sell-off, arguing that its payment infrastructure remains essential to small businesses. Praemium, Experience Co, Plenti, Aroa Biosurgery and Pointsbet reported encouraging quarterly updates, with Praemium's renewed platform inflows supporting confidence in its recovery. October 2024 PPS $194MTYR $237M